A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer.
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 290
- Registration Number
- NCT06284317
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT06068153
- Locations
- 🇪🇸
Hospital Universitario Y Politécnico La Fe, Valencia, Spain
🇦🇹Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck, Austria
🇨🇭Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718323
- Locations
- 🇫🇷
CHU - Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
🇫🇷Caen - CHU, Caen, France
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718297
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Caen - CHU, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 68
- Registration Number
- NCT05673187
- Locations
- 🇮🇪
St James's Hospital, Dublin, Ireland
🇮🇪University Hospital Limerick, Limerick, Ireland
🇧🇪Instiute Jules Bordet, Brussels, Belgium
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05601973
- Locations
- 🇮🇹
SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy
🇫🇷Chu Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 190
- Registration Number
- NCT05522660
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italy
🇮🇹Santa Maria della Misericordia Hospital, Perugia, Italy
🇮🇹Istituto Nazionale Tumori "Regina Elena", Roma, Italy
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT04908956
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Sinchon-dong, Korea, Republic of
🇪🇸Hospital General de Alicante, Alicante, Spain
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 95
- Registration Number
- NCT04245085
- Locations
- 🇩🇪
LungenClinic Grosshansdorf, Großhansdorf, Germany
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland